Načítá se...
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...
Uloženo v:
| Vydáno v: | Ther Adv Respir Dis |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7029533/ https://ncbi.nlm.nih.gov/pubmed/32066332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620906326 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|